Table 3.
KEGG pathway analysis of differentially expressed genes
| Pathway | KEGG | Input | Background | p-value | Genes |
|---|---|---|---|---|---|
| ID | number | number | |||
| PI3K-Akt signaling pathway | hsa04151 | 5 | 342 | 3.70E − 08 | PTK2, MET, TCL1A |
| RELN, EPO | |||||
| Jak-STAT signaling pathway | hsa04630 | 4 | 158 | 1.28E − 07 | IL12RB1, STAT5A, |
| STAT3, EPO | |||||
| HIF-1 signaling pathway | hsa04066 | 3 | 103 | 3.98E − 06 | PDK1, STAT3, EPO |
| Pathways in cancer | hsa05200 | 4 | 397 | 4.73E − 06 | PTK2, STAT5A, |
| MET, STAT3 | |||||
| Axon guidance | hsa04360 | 3 | 176 | 1.91E − 05 | PDK1, MET, PTK2 |
| Focal adhesion | hsa04510 | 3 | 203 | 2.91E − 05 | RELN, MET, PTK2 |
| Proteoglycans in cancer | hsa05205 | 3 | 205 | 3.00E − 05 | PTK2, MET, STAT3 |
| Cytokine-cytokine receptor interaction | hsa04060 | 3 | 265 | 6.36E − 05 | IL12RB1, MET, EPO |
| Inflammatory bowel disease (IBD) | hsa05321 | 2 | 66 | 1.880E − 04 | IL12RB1, STAT3 |
| Central carbon metabolism in cancer | hsa05230 | 2 | 67 | 1.936E − 04 | STAT5A, IL12RB1 |
| Prolactin signaling pathway | hsa04917 | 2 | 72 | 2.227E − 04 | STAT5A, STAT3 |
| Bacterial invasion of epithelial cells | hsa05100 | 2 | 78 | 2.603E − 04 | MET, PTK2 |
| ErbB signaling pathway | hsa04012 | 2 | 88 | 3.293E − 04 | STAT5A, PTK2 |
| AGE-RAGE signaling pathway in diabetic complications | hsa04933 | 2 | 101 | 4.310E − 04 | STAT5A, STAT3 |
The above results were analyzed using DAVID and KOBAS online analysis tools
PI3K-Akt: Phosphatidylinositol 3 kinase(PI3K) /protein kinase B(AKT), Jak-STAT: Janus kinase (JAK)/ signal transducer and activator of transcription (STAT), HIF-1: Hypoxia inducible factor-1 (HAF-1), ErbB: Receptor tyrosine-protein kinase erbB-2, i.e. Her2, human epidermal growth factor receptor 2 (HER2), AGE-RAGE: advanced glycation end products (AGE) / receptor for dvanced glycation end products (RAGE)